Effect of Curcumin on Liver enzymes and Liver T2*MRI in patients with Thalassemia.

Evaluation of the effect of oral Curcumin on Liver enzymes and Liver T2*MRI in patients with major and intermediate Thalassemia at Amirkabir hospital in Arak in 2020.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200807048328N1

Enrollment

Registered

2020-10-28

Start date

2020-06-21

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron Overload in Beta Thalassaemia Major and Intermedia patients. Thalassemia

Interventions

Intervention 1: Intervention group: participants in the intervention group will be given the drug curcumin karen containing 95% turmeric extract. This drug will be given as a capsule in the amount of

Eligibility

Sex/Gender

All

Age

5 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 5 years old. Patients diagnosed with Thalassemia major and intermedia. Having conscious satisfaction.

Exclusion criteria

Exclusion criteria: Pregnancy. History of liver disease. Consumption of drugs affecting liver metabolism and liver enzymes and ferritin levels. History of turmeric allergy. Having bleeding disease. Taking anticoagulants.

Design outcomes

Primary

Measure	Time frame
Aspartate aminotransferase. Timepoint: At the beginning of the study and every month for up to 6 months. Method of measurement: Patient blood sample.;Alanine transaminase. Timepoint: At the beginning of the study and every month for up to 6 months. Method of measurement: Patient blood sample.;Alkaline phosphatase. Timepoint: At the beginning of the study and every month for up to 6 months. Method of measurement: Patient blood sample.;Total bilirubin. Timepoint: At the beginning of the study and every month for up to 6 months. Method of measurement: Patient blood sample.;Direct bilirubin. Timepoint: At the beginning of the study and every month for up to 6 months. Method of measurement: Patient blood sample.;Serum Ferritin. Timepoint: At the beginning of the study and every month for up to 6 months. Method of measurement: Patient blood sample.;T2*-weighted imaging. Timepoint: At the beginning of the study and 6 months later. Method of measurement: Magnetic resonanse imaging machine.	—

Measure

Time frame

Aspartate aminotransferase. Timepoint: At the beginning of the study and every month for up to 6 months. Method of measurement: Patient blood sample.;Alanine transaminase. Timepoint: At the beginning of the study and every month for up to 6 months. Method of measurement: Patient blood sample.;Alkaline phosphatase. Timepoint: At the beginning of the study and every month for up to 6 months. Method of measurement: Patient blood sample.;Total bilirubin. Timepoint: At the beginning of the study and every month for up to 6 months. Method of measurement: Patient blood sample.;Direct bilirubin. Timepoint: At the beginning of the study and every month for up to 6 months. Method of measurement: Patient blood sample.;Serum Ferritin. Timepoint: At the beginning of the study and every month for up to 6 months. Method of measurement: Patient blood sample.;T2*-weighted imaging. Timepoint: At the beginning of the study and 6 months later. Method of measurement: Magnetic resonanse imaging machine.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArash Vahdati

Arak University of Medical Sciences

research@arakmu.ac.ir+98 86 3417 3645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026